1
|
Chen L, Qian W, Pan F, Li D, Yu W, Tong L, Yang Y, Xu Q, Ding J, Dai R, Xian W, Zhu X, Ren P, Zhu H. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement. Immunotherapy 2024; 16:143-159. [PMID: 38126157 DOI: 10.2217/imt-2023-0256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023] Open
Abstract
Aim: A novel CD19xCD3xCD28 trispecific antibody with a tandem single-chain variable fragments (scFv) structure was developed for the treatment of B-cell malignancies. Methods: The trispecific antibody in inducing tumor-directed T-cell activation and cytotoxicity was evaluated in vitro and in vivo and compared with its bispecific counterpart BiTE-CD19xCD3 lacking a CD28-targeting domain. Results: The trispecific antibody with a co-stimulatory domain exhibited augmented T-cell activation and memory T-cell differentiation capability and it induced faster tumor cell lysis than the bispecific antibody. RNAseq analysis revealed that the trispecific antibody modulates CD3/TCR complex-derived signal and upregulates antiapoptotic factors to influence the survival of T cells. Conclusion: By CD3/CD28 co-engagement, the trispecific antibody demonstrated its advantages in T-cell immunity and potential use as a more powerful and long-lasting T-cell engager.
Collapse
Affiliation(s)
- Li Chen
- CytoCares (Shanghai) Inc., Zhangjiang Hi-Tech Park, Shanghai, 201203, China
| | - Wenjing Qian
- CytoCares (Shanghai) Inc., Zhangjiang Hi-Tech Park, Shanghai, 201203, China
| | - Fangfang Pan
- CytoCares (Shanghai) Inc., Zhangjiang Hi-Tech Park, Shanghai, 201203, China
| | - Debin Li
- Novoprotein Scientific Inc., Wujiang Economic & Technological Development Zone, Suzhou, 215299, China
| | - Weiwei Yu
- GemPharmatech Co., Ltd, Jiangbei New Area, Nanjing, 210031, China
| | - Li Tong
- PharmaLegacy Laboratories, Pudong New Area, Shanghai, 201203, China
| | - Yingying Yang
- CytoCares (Shanghai) Inc., Zhangjiang Hi-Tech Park, Shanghai, 201203, China
| | - Qiming Xu
- CytoCares (Shanghai) Inc., Zhangjiang Hi-Tech Park, Shanghai, 201203, China
| | - Jianfeng Ding
- Novoprotein Scientific Inc., Wujiang Economic & Technological Development Zone, Suzhou, 215299, China
| | - Ruixue Dai
- CytoCares (Shanghai) Inc., Zhangjiang Hi-Tech Park, Shanghai, 201203, China
| | - Weiwei Xian
- CytoCares (Shanghai) Inc., Zhangjiang Hi-Tech Park, Shanghai, 201203, China
| | - Xufeng Zhu
- Novoprotein Scientific Inc., Wujiang Economic & Technological Development Zone, Suzhou, 215299, China
| | - Pu Ren
- CytoCares (Shanghai) Inc., Zhangjiang Hi-Tech Park, Shanghai, 201203, China
| | - Huaxing Zhu
- CytoCares (Shanghai) Inc., Zhangjiang Hi-Tech Park, Shanghai, 201203, China
- Novoprotein Scientific Inc., Wujiang Economic & Technological Development Zone, Suzhou, 215299, China
- Institute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, 200240, China
| |
Collapse
|
2
|
Zhao P, Cheng W, Liu C, Peng C, Shen Y, Yang Y, Sun C, Chang X, Wu J. Increased proportion of CD226 + CD14 + monocytes correlates with clinical features and laboratory parameters in patients with primary Sjögren's syndrome. Int J Rheum Dis 2023; 26:2460-2469. [PMID: 37792570 DOI: 10.1111/1756-185x.14936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2023] [Revised: 09/21/2023] [Accepted: 09/24/2023] [Indexed: 10/06/2023]
Abstract
OBJECTIVES CD226 is widely expressed on the surface of immune cells as a co-stimulatory receptor, which is involved in the development of many autoimmune diseases. The purpose of this study was to investigate the proportion of CD226 on CD14 + monocytes in the peripheral circulation of patients with primary Sjögren's syndrome (pSS) and the clinical significance of pSS. METHODS The proportion of CD226 on the surface of CD14 + monocytes was measured by flow cytometry in 45 pSS patients and 25 healthy controls (HC). The correlations between the proportion of CD226 + CD14 + monocytes and the clinical features and laboratory parameters of pSS were analyzed. Meanwhile, we analyzed the change in proportion of CD226 + CD14 + monocytes before and after treatment, and the clinical significance of pSS was evaluated. RESULTS The proportion of CD226 on CD14 + monocytes markedly increased in pSS patients compared to HC (p < .01). We found the proportion of CD226 + CD14 + monocytes was positively correlated with the disease activity and severity of pSS patients. The proportion of CD226 + CD14 + monocytes in pSS patients with decayed tooth, fatigue, interstitial lung disease (ILD), low WBC, high IgG, anti-Ro60, and anti-SSB positive increased compared to that in negative patients (p < .05). Furthermore, the proportion of CD226 + CD14 + monocytes was significantly higher in active patients than in nonactive patients (p < .01). Additionally, the proportion of CD226 + CD14 + monocytes decreased in seven pSS patients after treatment (p < .01). CONCLUSION Our study suggested that an increased CD226 proportion on CD14 + monocytes was associated with the clinical manifestations, disease activity, and prognosis of pSS patients. CD226+ CD14 + monocytes may present a potential target and a biomarker for the prognosis and therapy of pSS patients.
Collapse
Affiliation(s)
- Ping Zhao
- Department of Rheumatology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
| | - Wei Cheng
- Department of Rheumatology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Department of Dermatology, Changsu NO2 People's Hospital, Changshu, Suzhou, China
| | - Cuiping Liu
- Jiangsu Key Laboratory of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Cheng Peng
- Department of Rheumatology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Yu Shen
- Jiangsu Key Laboratory of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Yanhong Yang
- Department of Obstetrics and Gynecology, Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Chao Sun
- Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
| | - Xin Chang
- Department of Rheumatology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Jian Wu
- Department of Rheumatology, The First Affiliated Hospital of Soochow University, Suzhou, China
| |
Collapse
|
3
|
Yang ZZ, Kim HJ, Villasboas JC, Price-Troska T, Jalali S, Wu H, Luchtel RA, Polley MYC, Novak AJ, Ansell SM. Mass Cytometry Analysis Reveals that Specific Intratumoral CD4 + T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. Cell Rep 2020; 26:2178-2193.e3. [PMID: 30784598 PMCID: PMC6402596 DOI: 10.1016/j.celrep.2019.01.085] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Revised: 09/24/2018] [Accepted: 01/24/2019] [Indexed: 12/30/2022] Open
Abstract
Follicular lymphoma (FL) is an indolent B cell malignancy characterized by an extensive but poorly functional T cell infiltrate in the tumor microenvironment. Using mass cytometry, we identified at least 12 subsets of intratumoral CD4+ T cells, 3 of which were unique to FL biopsies versus control tissues. Of these subsets, the frequency of naive T cells correlated with improved patient survival. Although total PD-1+ T cell numbers were not associated with patient outcome, specific PD-1+ T cell subpopulations were associated with poor survival. Intratumoral T cells lacking CD27 and CD28 co-stimulatory receptor expression were enriched in FL and correlated with inferior patient outcomes. In vitro models revealed that CD70+ lymphoma cells played an important role in expanding this population. Taken together, our mass cytometry results identified CD4+ memory T cell populations that are poorly functional due to loss of co-stimulatory receptor expression and are associated with an inferior survival in FL. Yang et al. utilize mass cytometry (CyTOF) to characterize intratumoral T cells and explore the clinical relevance of T cell subsets in follicular lymphoma (FL). Clustering analysis reveals an immune signature with reduced expression of co-stimulatory molecules on intratumoral T cells that correlated with a poor prognosis in FL.
Collapse
Affiliation(s)
- Zhi-Zhang Yang
- Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
| | - Hyo Jin Kim
- Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Jose C Villasboas
- Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Tammy Price-Troska
- Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Shahrzad Jalali
- Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Hongyan Wu
- Department of Immunology, Medical College, China Three Gorges University, Yichang, Hubei, China
| | - Rebecca A Luchtel
- Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Mei-Yin C Polley
- Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Anne J Novak
- Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Stephen M Ansell
- Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
| |
Collapse
|
4
|
Braud VM, Biton J, Becht E, Knockaert S, Mansuet-Lupo A, Cosson E, Damotte D, Alifano M, Validire P, Anjuère F, Cremer I, Girard N, Gossot D, Seguin-Givelet A, Dieu-Nosjean MC, Germain C. Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. Oncoimmunology 2018; 7:e1423184. [PMID: 29721382 PMCID: PMC5927544 DOI: 10.1080/2162402x.2017.1423184] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Revised: 12/21/2017] [Accepted: 12/22/2017] [Indexed: 12/18/2022] Open
Abstract
Co-stimulatory and inhibitory receptors expressed by immune cells in the tumor microenvironment modulate the immune response and cancer progression. Their expression and regulation are still not fully characterized and a better understanding of these mechanisms is needed to improve current immunotherapies. Our previous work has identified a novel ligand/receptor pair, LLT1/CD161, that modulates immune responses. Here, we extensively characterize its expression in non-small cell lung cancer (NSCLC). We show that LLT1 expression is restricted to germinal center (GC) B cells within tertiary lymphoid structures (TLS), representing a new hallmark of the presence of active TLS in the tumor microenvironment. CD161-expressing immune cells are found at the vicinity of these structures, with a global enrichment of NSCLC tumors in CD161+ CD4+ and CD8+ T cells as compared to normal distant lung and peripheral blood. CD161+ CD4+ T cells are more activated and produce Th1-cytokines at a higher frequency than their matched CD161-negative counterparts. Interestingly, CD161+ CD4+ T cells highly express OX40 co-stimulatory receptor, less frequently 4-1BB, and display an activated but not completely exhausted PD-1-positive Tim-3-negative phenotype. Finally, a meta-analysis revealed a positive association of CLEC2D (coding for LLT1) and KLRB1 (coding for CD161) gene expression with favorable outcome in NSCLC, independently of the size of T and B cell infiltrates. These data are consistent with a positive impact of LLT1/CD161 on NSCLC patient survival, and make CD161-expressing CD4+ T cells ideal candidates for efficient anti-tumor recall responses.
Collapse
Affiliation(s)
- Véronique M. Braud
- Université Côte d'Azur, CNRS UMR7275, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), Valbonne, France
| | - Jérôme Biton
- Laboratory “Immune Microenvironment and Tumors”, Department “Cancer, Immunology, Immunotherapy”, INSERM UMRS 1138, Cordeliers Research Center, Paris, France
- University Pierre and Marie Curie/Paris VI, Paris, France
- University Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
| | - Etienne Becht
- Laboratory “Immune Microenvironment and Tumors”, Department “Cancer, Immunology, Immunotherapy”, INSERM UMRS 1138, Cordeliers Research Center, Paris, France
- University Pierre and Marie Curie/Paris VI, Paris, France
- University Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
| | - Samantha Knockaert
- Laboratory “Immune Microenvironment and Tumors”, Department “Cancer, Immunology, Immunotherapy”, INSERM UMRS 1138, Cordeliers Research Center, Paris, France
- University Pierre and Marie Curie/Paris VI, Paris, France
- University Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
| | - Audrey Mansuet-Lupo
- Laboratory “Immune Microenvironment and Tumors”, Department “Cancer, Immunology, Immunotherapy”, INSERM UMRS 1138, Cordeliers Research Center, Paris, France
- University Pierre and Marie Curie/Paris VI, Paris, France
- University Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
- Department of Pathology, Hôpitaux Universitaires Paris Centre, AP-HP, Paris, France
| | - Estelle Cosson
- Université Côte d'Azur, CNRS UMR7275, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), Valbonne, France
| | - Diane Damotte
- Laboratory “Immune Microenvironment and Tumors”, Department “Cancer, Immunology, Immunotherapy”, INSERM UMRS 1138, Cordeliers Research Center, Paris, France
- University Pierre and Marie Curie/Paris VI, Paris, France
- University Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
- Department of Pathology, Hôpitaux Universitaires Paris Centre, AP-HP, Paris, France
| | - Marco Alifano
- University Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
- Department of Thoracic Surgery, Hôpitaux Universitaires Paris Centre, AP-HP, Paris, France
| | - Pierre Validire
- Laboratory “Immune Microenvironment and Tumors”, Department “Cancer, Immunology, Immunotherapy”, INSERM UMRS 1138, Cordeliers Research Center, Paris, France
- Department of Pathology, Institut Mutualiste Montsouris, Paris, France
| | - Fabienne Anjuère
- Université Côte d'Azur, CNRS UMR7275, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), Valbonne, France
| | - Isabelle Cremer
- Laboratory “Immune Microenvironment and Tumors”, Department “Cancer, Immunology, Immunotherapy”, INSERM UMRS 1138, Cordeliers Research Center, Paris, France
- University Pierre and Marie Curie/Paris VI, Paris, France
- University Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
| | - Nicolas Girard
- University of Lyon, University Lyon 1, Lyon, France
- Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France
| | - Dominique Gossot
- Thoracic Department, Institut du Thorax Curie-Montsouris, Institut Mutualiste Montsouris, Paris, France
| | - Agathe Seguin-Givelet
- Thoracic Department, Institut du Thorax Curie-Montsouris, Institut Mutualiste Montsouris, Paris, France
- Paris 13 University, Sorbonne Paris Cité, Faculty of Medicine SMBH, Bobigny, France
| | - Marie-Caroline Dieu-Nosjean
- Laboratory “Immune Microenvironment and Tumors”, Department “Cancer, Immunology, Immunotherapy”, INSERM UMRS 1138, Cordeliers Research Center, Paris, France
- University Pierre and Marie Curie/Paris VI, Paris, France
- University Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
| | - Claire Germain
- Laboratory “Immune Microenvironment and Tumors”, Department “Cancer, Immunology, Immunotherapy”, INSERM UMRS 1138, Cordeliers Research Center, Paris, France
- University Pierre and Marie Curie/Paris VI, Paris, France
- University Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
| |
Collapse
|